PMC11 IMPUTE INCOMPLETE PATIENT-LEVEL MEDICAL COSTS  by Guan, S et al.
A388 Paris Abstracts
PMC7
THE NATURE AND SCALE OF INADEQUATE REPORTING OF 
DICHOTOMOUS OUTCOMES FROM SIX SYSTEMATIC REVIEWS
Bhanderi M, Dimri S, Mahajan A, Ubhadiya BS, Narvilkar P, Agrawal R, Singh N
Heron Health Private Ltd, Chandigarh, India
OBJECTIVES: Inadequate reporting of outcomes is a major problem while performing 
meta-analysis. The objective of this study is to estimate the nature and scale of inade-
quate reporting of dichotomous outcomes. METHODS: Reporting quality of dichoto-
mous outcomes (efﬁcacy and safety) was analysed across six systematic reviews 
conducted in four disease areas namely oncology (non-small cell lung cancer, color-
ectal cancer and ovarian cancer), overactive bladder, multiple sclerosis and rheumatoid 
arthritis. Reporting quality was considered inadequate when either number of patients 
analysed (N) was not reported or percentage was reported improperly. Reporting of 
percentage was considered as improper when the number of patients with outcome 
(n) could not be calculated from the given percentage. This may be the case when 
more than one value corresponds to same reported percentage (example 5% of 498 
could have values between 23 and 27). Analyses were conducted using STATA 9.2. 
RESULTS: In total, 6408 reported outcomes were included in the analysis. Inadequate 
reporting of dichotomous outcomes was frequent and observed for 691 (10.78%) 
outcomes. The estimate of inadequate reporting varied across selected reviews and 
ranged from 7.36% to 17.41% in overactive bladder and multiple sclerosis, respec-
tively. Estimate of inadequate reporting was similar for the safety and efﬁcacy out-
comes (10.53% and 11.19%, respectively). Improper reporting of percentage 
contributed for approximately two-third (65.56%) of the inadequately reported out-
comes whereas for the remaining outcomes, N was missing. CONCLUSIONS: Inade-
quate reporting of dichotomous outcome was frequently observed among the selected 
reviews. It was observed that reporting of percentages in published reports are often 
imperfect (due to rounding of values). This leads to loss of data available for meta-
analyses as number of patients with outcome could not be calculated accurately. Our 
results are indicative of outcome reporting bias which needs to be investigated 
further.
PMC8
USING ATLAS.TI AS A TOOL TO EXTRACT AND SYNTHESIZE DATA 
OBTAINED IN LITERATURE REVIEWING
Stafford MR1, Houghton K1, Stull D2
1United BioSource Corporation, London, UK, 2United BioSource–Europe, London, UK
OBJECTIVES: ATLAS.ti software was designed for the qualitative analysis of textual, 
graphical, audio, and video data. Using ATLAS.ti, qualitative data can be systemati-
cally analyzed and the relevant data extracted. It is used extensively in the analysis of 
data obtained in interviews and focus groups. We explored its use in extracting, ana-
lyzing, and synthesizing literature from a large, focused review of pain relief. 
METHODS: A comprehensive search of studies published between 1998–2008 was 
conducted in Embase.com comparing outcomes and adverse events following different 
pain relief treatments across a range of therapeutic areas. Relevant studies were 
imported into ATLAS.ti and were coded and analyzed. On completion of each study 
review and data coding, ‘outputs’ for codes were extracted. ‘Outputs’ contained all 
data related to a code and could consist of either singular codes such as ‘therapeutic 
area’ or combinations of codes such as ‘outcome’ and ‘superiority [of one drug against 
another]’. Data were categorized according to emerging themes regarding outcomes 
and adverse events (AEs) associated with the pain relief treatments included in the 
review. RESULTS: Following a 2-stage screening process, 232 relevant, published 
studies were imported into ATLAS.ti for full review and coding. Information on 
sample studied, therapeutic area, outcomes, AEs, and other trial data was coded. 
ATLAS.ti enabled identiﬁcation of the most common therapeutic areas where the 
target product had been studied: rheumatology, acute pain, chronic pain and urology. 
Further, speciﬁc comparisons between the target product and other pain relievers 
(COX-2s, NSAIDS, and opioids) on efﬁcacy and AEs were possible by coding key 
results from the studies. Versatile cross-comparisons were possible because of the 
detailed coding. CONCLUSIONS: ATLAS.ti can be a useful tool for extracting and 
synthesizing a large volume of literature. It enabled development of new key product 
messages by allowing for emergent themes from a large, published literature.
PMC9
REDUCING BIAS IN A RETROSPECTIVE CASE-CONTROL STUDY: AN 
APPLICATION OF PROPENSITY SCORE MATCHING.
Exuzides A1, Colby C1, Goldman J2, Waaler A3
1ICON Clinical Research, San Francisco, CA, USA, 2ICON Medical Imaging, San Francisco, 
CA, USA, 3GE Healthcare, Horten, Norway
OBJECTIVES: Selection bias is common in observational studies. When treatment 
selection is non-random , cases and controls frequently show imbalances in patient 
characteristics. To reduce such imbalances in a retrospective case-control study, we 
used propensity score matching. We present the derivation of propensity scores, selec-
tion of controls, and compare patient characteristics before and after matching. 
METHODS: We utilized the largest hospital service-level database in the U.S. We 
identiﬁed 2,588,722 adult patients undergoing inpatient echocardiography between 
January 2003 and October 2005 of which 2,900 had diagnoses for critical illness 
(heart failure, acute myocardial infarction, arrhythmia, respiratory failure, pulmonary 
embolism, emphysema, and pulmonary hypertension) and who also received a contrast 
agent (Perﬂutren Protein-Type A Microspheres Injectable Suspension, USP). Patients 
receiving other contrast agents were excluded from the study. To control for differ-
ences between patients receiving contrast echocardiography (cases) to those who 
received non-contrast echocardiography (controls), we used propensity score match-
ing. A stepwise logistic regression was used to model treatment choice (contrast vs. 
non-contrast). Variables used in the construction of the propensity score included 
comorbidities , demographic factors , hospital-speciﬁc factors , level of care, and 
mechanical ventilation status. Cases were matched to 4 controls using the nearest 
neighbor matching algorithm based on differences in propensity scores among cases 
and controls. RESULTS: The nearest neighbor matching algorithm successfully identi-
ﬁed 4 matches for each of the 2900 contrast patients. Prior to matching, 23 out of 
the 26 patient characteristics showed statistically signiﬁcant differences between cases 
and controls (P  0.01). These characteristics included mechanical ventilation status, 
ICU status, and the Deyo-Charlson Comorbidity Score. After matching, one variable 
remained statistically signiﬁcant (higher concomitant medication usage among cases; 
P  0.006). CONCLUSIONS: The use of propensity score matching can reduce selec-
tion bias in a retrospective case-control study and, thus, create well-balanced groups 
of cases and controls for the analysis.
PMC10
HOW TO MAKE USE OF AVAILABLE SURVIVAL EVIDENCE IN AN 
INDIRECT COMPARISON
Ouwens M1, Philips Z2
1Mapi Values Netherlands B.V., Houten, The Netherlands, 2Mapi Values UK, Bollington , 
Cheshire, UK
OBJECTIVES: Therapies for oncology often effect time-to-event statistics like overall 
survival and progression free survival. In the literature, these time-to-event statistics 
are summarized by median time-to-event, percentage of people having had the event 
at a speciﬁc point in time and hazard rates, among others. Although pooling based 
on individual patient data would be preferred, we still encounter situations where only 
aggregated data is available. For these situations, the hazard ratios can be pooled. 
However, many high quality papers would be ignored, if publications were only 
regarded once the hazard ratio is presented. We therefore searched for methods to 
transform the different outcomes to the same scale and to pool based on as much 
information as possible. METHODS: A review was performed with respect to the 
pooling of different time-to-event outcomes. Mixed Treatment Comparisons were 
performed using the methods to assess their usability. RESULTS: For cost-effectiveness 
models, a distribution (exponential, weibull, among others) of the time-to-event sta-
tistic is often used to obtain the average of the time-to-event statistic for the compara-
tor arm. This distribution can also be used to transform the median and the ‘percentage 
having had an event at a speciﬁc time point’ into hazard rates. Comparing the trans-
formed medians with the hazard rates for publications in which both are presented 
implied a way to check the validity of assumptions. CONCLUSIONS: Although the 
way information about time-to-event statistics is presented may differ across publica-
tions, it is often possible to pool the different types of information. This implied the 
inclusion of papers which otherwise couldn’t be used and a reduction of the uncer-
tainty in the cost-effectiveness outcomes.
CONCEPTUAL PAPERS & RESEARCH ON METHODS – Cost Methods
PMC11
IMPUTE INCOMPLETE PATIENT-LEVEL MEDICAL COSTS
Guan S1, Peeters P2, Pedotti P1, Van Engen AK1
1Quintiles Consulting, Hoofddorp, The Netherlands, 2Quintiles Consulting, Levallois-Perret, 
France
OBJECTIVE: To address the common issue of incomplete data in cost-effective analy-
sis, we imputed missing cost components at the patient level using multiple imputation 
(MI) techniques. METHODS: A study cohort with concomitant medication, hospital-
ization and outpatient-visit costs was derived from the population of a randomised 
clinical trial comparing two treatments. On a total of 132 subjects without missing 
data, a pattern of missingness was created so that 25% of subjects had missing hos-
pitalization costs and 50% (including the above 25%) had missing concomitant medi-
cation costs. The average total costs (sum of the three components) obtained using 
MI techniques (propensity score [PS], regression and Markov Chain Monte Carlo 
[MCMC]), complete case analysis (CCA) and available case analysis (ACA) were 
compared with actual costs. In imputation models, response variables were the loga-
rithm-transformed medication and hospitalization costs; covariates were age, gender, 
race, region, treatment arm, number of adverse events, survival time, treatment dis-
continuation, and outpatient-visit cost (logarithm-transformed). RESULTS: Average 
total costs made up of three cost components are given by treatment A versus treat-
ment B. Actual total cost: £16,527 vs. £18,484. Estimated costs: CCA: £17,317 vs. 
£15,400; ACA: £13,407 vs. £15,361; MI-PS: £16,941 vs. £19,156; MI-Regression: 
£16,404 vs. £19,056; MI-MCMC: £16,584 vs. £18,947. CONCLUSIONS: Treatment 
B was actually more expensive than treatment A. CCA gave opposite results; while 
ACA underestimated total costs. Regression gave better results than PS, as a regression 
model was ﬁtted for each missing cost component, with the previous variables as 
covariates. MCMC using Bayes’ theorem with a non-informative prior makes 
minimum assumption for the data and gave the best imputation results. Under the 
assumption of missing at random, MCMC could be a useful imputation technique 
applied to the patient-level missing costs, to permit a more realistic cost-effective 
analysis.
